Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK),
safety and tolerability following single and multiple oral doses of 5mg to 20 mg SHR3824 in
Type 2 diabetes mellitus patients.